PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy.


Journal

NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891

Informations de publication

Date de publication:
05 May 2021
Historique:
received: 11 11 2019
accepted: 12 11 2020
entrez: 6 5 2021
pubmed: 7 5 2021
medline: 7 5 2021
Statut: epublish

Résumé

Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast Recurrence Score

Identifiants

pubmed: 33953182
doi: 10.1038/s41523-021-00246-4
pii: 10.1038/s41523-021-00246-4
pmc: PMC8099872
doi:

Types de publication

Journal Article

Langues

eng

Pagination

47

Références

Oncologist. 2018 Mar;23(3):297-305
pubmed: 29133514
Curr Med Res Opin. 2016 Jul;32(7):1217-24
pubmed: 26971372
PLoS One. 2017 Oct 18;12(10):e0185753
pubmed: 29045452
Oncologist. 2018 Jul;23(7):768-775
pubmed: 29371476
Med J Aust. 2013 Aug 5;199(3):205-8
pubmed: 23909545
Breast Cancer Res Treat. 2019 Jun;175(2):389-399
pubmed: 30796651
N Engl J Med. 2015 Nov 19;373(21):2005-14
pubmed: 26412349
J Natl Cancer Inst. 2013 Dec 18;105(24):1897-906
pubmed: 24203987
J Natl Compr Canc Netw. 2018 Nov;16(11):1362-1389
pubmed: 30442736
NPJ Breast Cancer. 2018 Aug 20;4:27
pubmed: 30155517
J Natl Cancer Inst. 2014 Apr 28;106(5):
pubmed: 24777111
Breast Cancer Res Treat. 2017 Jun;163(2):303-310
pubmed: 28243896
NPJ Breast Cancer. 2016 Jun 08;2:16017
pubmed: 28721379
J Natl Cancer Inst. 2008 Feb 6;100(3):207-12
pubmed: 18230798
J Med Econ. 2012;15(6):1167-75
pubmed: 22853442
Bull Cancer. 2011 Jul;98(7):E69-79
pubmed: 21684837
NPJ Breast Cancer. 2018 Nov 14;4:37
pubmed: 30456299
Lancet. 2012 Feb 4;379(9814):432-44
pubmed: 22152853
J Clin Oncol. 2006 Aug 10;24(23):3726-34
pubmed: 16720680
J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
pubmed: 21960707
PLoS One. 2013 Jun 27;8(6):e68252
pubmed: 23826382
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
Breast Cancer Res Treat. 2011 Apr;126(3):797-802
pubmed: 21197567
J Oncol Pract. 2017 Dec;13(12):784-790
pubmed: 29232539
Eur J Cancer. 2016 Oct;66:104-13
pubmed: 27544930
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
BMC Cancer. 2017 Apr 13;17(1):265
pubmed: 28407750
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
NPJ Breast Cancer. 2017 Sep 8;3:33
pubmed: 28900633
PLoS One. 2012;7(5):e37379
pubmed: 22662150
Breast Cancer Res Treat. 2017 Oct;165(3):573-583
pubmed: 28664507
Breast. 2019 Apr;44:39-45
pubmed: 30634106
Lancet Oncol. 2010 Jan;11(1):55-65
pubmed: 20005174
NPJ Breast Cancer. 2017 Sep 8;3:32
pubmed: 28900632
Br J Cancer. 2014 Aug 26;111(5):837-42
pubmed: 25003667
Breast. 2017 Jun;33:191-199
pubmed: 28441617

Auteurs

Francesco Cognetti (F)

Università La Sapienza di Roma, Dipartimento Medicina Clinica e Molecolare, Rome, Italy. francesco.cognetti@ifo.gov.it.

Riccardo Masetti (R)

Policlinico Universitario Agostino Gemelli, IRCCS, Roma, Italy.

Alessandra Fabi (A)

IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Giulia Bianchi (G)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Donatella Santini (D)

Policlinico Sant'Orsola Malpighi, Bologna, Italy.

Alessia Rognone (A)

Ospedale San Raffaele, Milano, Italy.

Giovanna Catania (G)

IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Domenico Angelucci (D)

Ospedale Gaetano Bernabeo, Ortona, Italy.

Giuseppe Naso (G)

Policlinico Umberto I, Roma, Italy.

Mario Giuliano (M)

Azienda Ospedaliera Universitaria Federico II, Napoli, Italy.

Lucia Vassalli (L)

ASST Spedali Civili, Brescia, Italy.

Patrizia Vici (P)

IRCCS Regina Elena National Cancer Institute, Roma, Italy.

Giovanni Scognamiglio (G)

Ospedale Valduce, Como, Italy.

Daniele Generali (D)

ASST di Cremona, Cremona, Italy.

Alberto Zambelli (A)

ASST Papa Giovanni XXIII, Bergamo, Italy.

Marco Colleoni (M)

Istituto Europeo di Oncologia, Milano, Italy.

Corrado Tinterri (C)

Istituto Clinico Humanitas, Rozzano, Italy.

Francesco Scanzi (F)

IRCCS Multimedica, Sesto San Giovanni, Italy.

Leonardo Vigna (L)

Azienda Ospedaliera San Camillo Forlanini, Roma, Italy.

Paola Scavina (P)

Azienda Ospedaliera San Giovanni - Addolorata, Roma, Italy.

Teresa Gamucci (T)

Ospedale SS. Trinità, Sora, Italy.

Emilia Marrazzo (E)

Istituto Clinico Humanitas, Rozzano, Italy.

Angelo Fedele Scinto (AF)

Ospedale San Giovani Calibita Fatebenefratelli, Roma, Italy.

Rossana Berardi (R)

Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Torrette, Italy.

Maria Agnese Fabbri (MA)

Ospedale di Belcolle, Viterbo, Italy.

Graziella Pinotti (G)

Ospedale di Circolo e Fondazione Macchi, Varese, Italy.

Daniela Franco (D)

Ospedale Nuovo Regina Margherita, Roma, Italy.

Daniela Andreina Terribile (DA)

Policlinico Universitario Agostino Gemelli, IRCCS, Roma, Italy.

Giuseppe Tonini (G)

Policlinico Universitario Campus Biomedico, Roma, Italy.

Daniela Cianniello (D)

Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy.

Sandro Barni (S)

ASST BG Ovest Ospedale Treviglio, Treviglio, BG, Italy.

Classifications MeSH